AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies
Event:
ESC Congress 2025
Topic:
Pharmacotherapy
Session:
Pharmacotherapy to improve outcomes in coronary disease
